Scientific article

Peptides as cancer vaccines

Published inCurrent Opinion in Pharmacology, vol. 47, p. 20-26
Publication date2019

Cancer vaccines based on synthetic peptides are a safe, well-tolerated immunotherapy able to specifically stimulate tumor-reactive T cells. However, their clinical efficacy does not approach that achieved with other immunotherapies such as immune checkpoint blockade. Nevertheless, major advances have been made in selecting tumor antigens to target, identifying epitopes binding to classical and non-classical HLA molecules, and incorporating these into optimal sized peptides for formulation into a vaccine. Limited potency of currently used adjuvants and the immunosuppressive tumor microenvironment are now understood to be major impediments to vaccine efficacy that need to be overcome. Rationally designed combination therapies are now being tested and should ultimately enable peptide vaccination to be added to immuno-oncology treatment options.

  • Autre - Association Frédéric Fellay and Fond'action contre le cancer
Citation (ISO format)
CALVO TARDON, Marta et al. Peptides as cancer vaccines. In: Current Opinion in Pharmacology, 2019, vol. 47, p. 20–26. doi: 10.1016/j.coph.2019.01.007
Main files (1)
Article (Published version)
ISSN of the journal1471-4892

Technical informations

Creation09/04/2019 11:28:00 AM
First validation09/04/2019 11:28:00 AM
Update time03/15/2023 6:08:14 PM
Status update03/15/2023 6:08:14 PM
Last indexation05/05/2024 3:23:02 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack